Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Use of immune checkpoint inhibitors (ICIs) in solid organ transplant recipients (SOTRs) with
advanced skin cancers presents a significant clinical management dilemma. SOTRs and …

Melanoma is a cancer of the pigment-producing cells of the body and its incidence is rising.
Targeted inhibitors that act against kinases in the MAPK pathway are approved for BRAF …

Simple Summary Melanocytes are the pigment-producing cells in the skin that help to
protect it against damaging solar ultraviolet radiation. As they engage in this function, they …

Simple Summary Neoadjuvant therapy for locally advanced disease or potentially
resectable metastatic melanoma is expected to improve operability and clinical outcomes …

Adjuvant immunotherapy (IO) and targeted therapy (TT) have improved relapse‐free survival
(RFS) in patients with stage III melanoma, although about 25% of them relapse within a year …

The presence of ulceration in melanoma is associated with poor clinical outcomes and is the
third most powerful predictor of survival in the AJCC Melanoma Staging System after tumor …

Aim We conducted a systematic review and evidence gap mapping to explore the existing
supportive care interventions and their impact on well‐being outcomes for melanoma …

Patients with resected stage IIIB, IIIC and IIID melanomas have a high risk of recurrence.
Therefore, an appropriate protocol for stage III melanoma is needed. Since adjuvant …

Background Neoadjuvant–adjuvant therapy for locally advanced or potentially resectable
metastatic melanoma was expected to improve operability and clinical outcomes over …